SCHEMBL4066634

SCHEMBL4066634

O=c1[nH]cnc2cc(CO)ccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 9/20 0.58
CHEK1 O14757 2/20 0.58
PIM1 P11309 2/20 0.58
ALDH1A1 P00352 1/20 0.58
RPS6KA3 P51812 1/20 0.58
PDPK1 O15530 1/20 0.51
CA12 O43570 1/20 0.51
ALOX15 P16050 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
CA9 Q16790 1/20 0.51
TNKS2 Q9H2K2 1/20 0.51
ROCK2 O75116 1/20 0.51
IP6K1 Q92551 4/20 0.50
IP6K3 Q96PC2 1/20 0.50
IP6K2 Q9UHH9 1/20 0.50
KDM4A O75164 1/20 0.47
KDM4B O94953 1/20 0.47
KDM5C P41229 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
KDM5B Q9UGL1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22980875 0.87 IP6K1 (0.66) PARP1CHEK1PIM1PDPK1CA12
SCHEMBL29136065 0.84 PARP1 (0.53) PARP1CHEK1PIM1ALDH1A1RPS6KA3
SCHEMBL24617507 0.83 PARP1 (0.58) PARP1CHEK1PIM1ALDH1A1RPS6KA3
SCHEMBL5097264 0.81 PARP1 (0.56) PARP1CHEK1PIM1ALDH1A1RPS6KA3
SCHEMBL27947189 0.81 PARP1 (0.55) PARP1CHEK1PIM1ALDH1A1RPS6KA3
SCHEMBL16538688 0.80 PARP1 (0.58) PARP1CHEK1PIM1ALDH1A1RPS6KA3
SCHEMBL25275583 0.80 PARP1 (0.61) PARP1CHEK1PIM1ALDH1A1RPS6KA3
SCHEMBL4870787 0.78 PARP1 (0.53) PARP1CHEK1PIM1ALDH1A1RPS6KA3
SCHEMBL29873118 0.77 PARP1 (0.74) PARP1CHEK1PIM1ALDH1A1RPS6KA3
SCHEMBL1663179 0.77 PARP1 (0.74) PARP1CHEK1PIM1ALDH1A1RPS6KA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612075-B2 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2009-11-03 US disclosed
US-7612075-B2 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2009-11-03 US disclosed
US-7612075-B2 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2009-11-03 US disclosed
EP-1208097-B1 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS AVENTIS PHARMA INC (US) 2009-02-18 EP disclosed
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2004-05-27 US disclosed
CN-1420882-A Substd. oxoazaheterocyclyl compounds AVENTIS PHARM PROD INC (US) 2003-05-28 CN disclosed
EP-1208097-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS Aventis Pharmaceuticals Inc. (US) 2002-05-29 EP disclosed
WO-2001007436-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS AVENTIS PHARMACEUTICALS INC. (US) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds F13B, F9, F11 PARP1 1298/4885CHEK1 4009/4885PIM1 4823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.